Pharmafile Logo

Cell and gene therapy manufacturing

- PMLiVE

Christina Coughlin to leave Immunocore for Tmunity

UPenn pioneers building their own biotech company

Training the next generation of biotech leaders

Blue Latitude Health speaks to Dr Ivan Wall, Reader in Cell & Gene Therapy Bioprocessing at University College London, to find out about the future of cell and gene therapy,...

Blue Latitude Health

- PMLiVE

Alcon spin-off prompts Novartis downgrade by Moody’s

Selling off Alcon concentrates business in riskier areas

- PMLiVE

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

Final European approval around the corner - but reimbursement and specialist centres among outstanding issues

- PMLiVE

Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

New funding will help London build on its gene therapy expertise

- PMLiVE

Freeline raises £88m to accelerate haemophilia gene therapy

Spin-out from London university joins fast-developing field

- PMLiVE

New trial results suggest CAR-T effects are durable in lymphoma

Novartis and Celgene/Juno release longer term data on important lymphoma indication at EHA

- PMLiVE

Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

Big departure from repurposing - Spark's Fraser Wright comes on board

- PMLiVE

Novartis bribery probe in Greece ‘could affect general election’

The pharma giant allegedly gave “bundles of cash” to civil servants, doctors and politicians

- PMLiVE

ICER says price of Amgen/Novartis’ Aimovig is OK – if used last-line

Recommends the drug should only be used in patients who have exhausted other prevention options

- PMLiVE

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links